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Lipid peroxidation of cell membranes stands out as an
important mechanism underlying endothelial cell damage,
myocardial dysfunction and organ failure during severe
sepsis and septic shock. Injurious oxidation originates from
sepsis-induced hyperproduction of reactive oxygen species
that overwhelm and exhaust endogenous antioxidant 
(e.g. intracellular glutathione) defence mechanisms [1].
Hence, adding antioxidants to standard treatment holds
evident promise for controlling organ failure in sepsis.
N-acetylcysteine (NAC) is one of the most extensively
studied antioxidants. NAC is a safe drug with a wide
toxic–therapeutic window, as documented by years of clinical
experience in patients with liver failure due to paracetamol
overdose [2]. Many potentially beneficial and protective
effects of NAC have been demonstrated in experimental
endotoxic and septic conditions. As a thiol-containing
compound, NAC scavenges free oxygen radicals and
replenishes depleted body glutathione stores. NAC also
suppresses the activation of neutrophils and macrophages
[3], attenuates leukocyte–endothelial cell adhesion and
capillary leakage [4], and blocks the release of tumour
necrosis factor alpha and IL-8, probably by modulating gene
expression of these mediators at the transcriptional level [5].
Only few clinical trials have investigated NAC as an adjuvant
treatment in human sepsis. In this context, the study of Emet
and colleagues is welcomed. These authors found that early
infusion of NAC in severe septic patients did not affect
cytokine levels, gastric intramucosal pH, oxygenation/
haemodynamic variables and outcome [6]. The results of this
‘negative’ clinical trial are in line with those of a recently
published study in animals. Vassilev and colleagues
administered NAC (150 mg/kg bolus, followed by 20 mg/kg
per hour for 11 hours) after 12 hours of endotoxaemia in
volume-resuscitated pigs. NAC significantly elevated
glutathione concentrations but failed to improve gas
exchange, metabolism and any systemic, pulmonary or
hepatosplanchnic parameter [7]. The reason(s) why these
investigators failed to reproduce or confirm the more
favourable results from previous animal and human studies
are not easily clarified. Nevertheless, the timing and dosing of
the NAC infusion appear to be of vital importance.
Most of the animal data were obtained in pretreatment or early
post-treatment studies. In that way, they are of limited
relevance to the clinical setting. Clinical studies produced
controversial results. NAC treatment during the first hours of
severe clinical sepsis and septic shock decreased peroxidative
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Abstract
The high morbidity and mortality of severe sepsis and septic shock fosters a continuous search for
novel therapies that go beyond pure correction of oxygenation and hemodynamics. Within this scope,
N-acetylcysteine shows great promise. Beside proven anti-oxidant, anti-inflammatory and cyto-
protective effects, N-acetylcysteine does also ensure endothelial protection and enhances micro-
vascular blood flow. Studies that put these highly favourable properties to the clinical test remain
scarce but are definitely needed to determine whether N-acetylcysteine has a place in our therapeutic
armamentarium against sepsis.
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stress [8], enhanced cardiac output and tissue oxygenation
[9], and improved hepatic function [10] and respiratory
function [11]. Delayed administration, however, failed to
improve tissue oxygenation [12] and adversely affected survival
in critically ill patients with established organ failure [13].
The dose of NAC in sepsis is based upon the administration
protocol in patients treated for paracetamol poisoning.
However, the rationale for using this dose in critically ill septic
patients has never been questioned or challenged. A
significant increase in cardiac output along with a systemic
vasodilatation is commonly described when a high dose of
NAC is infused over a short period [9,10]. These
haemodynamic changes appear to be short lived, however,
and they probably merely reflect the volume effect and the
high plasma concentrations that are obtained after
administration of the 150 mg/kg bolus dose [14]. Of more
concern is the worsening of organ failure, and particularly
cardiovascular failure, that has been described when NAC
infusion was continued beyond 24 hours. Peake and
colleagues demonstrated that administration of NAC in
septic shock caused depression of cardiovascular
performance, as indicated by a decrease in the cardiac
output and the mean arterial pressure [15]. This finding was
corroborated by Molnar and colleagues, who observed a
higher need for inotropic support in a cohort of critically ill
patients treated with NAC for longer than 24 hours [13].
Many issues regarding the use of NAC in septic patients
have received remarkedly poor attention or remain
unresolved. The pharmacokinetics and pharmodynamics of
the drug are virtually unknown. It remains to be determined
whether and how NAC influences basic cellular processes
such as bacterial clearance, neutrophil–endothelial cell
interplay and apoptosis. Finally, more information is needed
about possible drug interactions and toxic effects of NAC or
its metabolites.
In summary, as indicated by the study of Emet and colleagues
[6], any clinical benefit of NAC in sepsis remains to be proven.
The timing and dosing of NAC in relation with onset, evolution
and probably even severity of sepsis seem to be crucial
determinants of its in vivo activity. Surviving sepsis requires
rapid and sustained haemodynamic stabilisation and
containment of organ failure. Any drug that does not attain or
even jeopardises these goals should be avoided. We definitely
need a large trial using well-defined endpoints to consider the
real value of NAC as an adjuvant treatment in sepsis.
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